Low ratio of n3:n6 fatty acids correlates with CAD progression

Low ratio of n3:n6 fatty acids correlates with CAD progression
For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

(HealthDay)—For statin-treated patients with coronary artery disease, decreases in the ratio of serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) correlate with atherosclerosis progression, according to research published in the Jan. 1 issue of The American Journal of Cardiology.

Tsuyoshi Nozue, M.D., of the Yokohama Sakae Kyosai Hospital in Japan, and colleagues evaluated the effects of serum n-3 to n-6 PUFA ratios on in 101 statin-treated patients with coronary artery disease who were evaluated using virtual histology ultrasound. The patients were assessed at the time of percutaneous coronary intervention and after eight months of statin therapy.

At follow-up, the researchers found that 46 percent of patients showed atheroma progression and 54 percent exhibited atheroma regression. There were significant negative correlations seen for the change in plaque volume and in the change in fibrous component volume with the changes in the ratios of eicosapentaenoic acid (EPA)/arachidonic acid (AA), docosahexaenoic acid (DHA)/AA, and EPA+DHA/AA. The change in EPA+DPA/AA ratio was a significant predictor of the percentage change in both plaque volume and fibrous component volume in multivariate analysis.

"In conclusion, decreases in serum n-3 to n-6 polyunsaturated fatty acid ratios are associated with progression in coronary atherosclerosis evaluated using virtual histology intravascular ultrasound in statin-treated patients with ," the authors write.

More information: Abstract
Full Text

Related Stories

Drug may reduce coronary artery plaque

date Oct 12, 2008

Research presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), suggests that olmesartan, a drug commonly used to treat ...

Recommended for you

1950s drug is future heart treatment

date May 22, 2015

Oxford University researchers have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Time is muscle in acute heart failure

date May 21, 2015

Urgent diagnosis and treatment in acute heart failure has been emphasised for the first time in joint recommendations published today in European Heart Journal.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.